Next Article in Journal
Artificial Intelligence Used for Diagnosis in Facial Deformities: A Systematic Review
Previous Article in Journal
Effects of NF-κB Inhibitor on Sepsis Depend on the Severity and Phase of the Animal Sepsis Model
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Relationship between the Laboratory Biomarkers of SARS-CoV-2 Patients with Type 2 Diabetes at Discharge and the Severity of the Viral Pathology

by
Patricia-Andrada Reștea
1,
Ștefan Țigan
2,
Laura Grațiela Vicaș
3,*,
Luminita Fritea
4,
Mariana Eugenia Mureșan
4,
Felicia Manole
5,* and
Daniela Elisabeta Berdea
6
1
Department of Preclinical Discipline, Doctoral School of Biomedical Science, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania
2
Department of Medical Informatics and Biostatistics “Iuliu Hatieganu”, University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
3
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania
4
Department of Preclinical Discipline, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania
5
Department of Surgery, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania
6
Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania
*
Authors to whom correspondence should be addressed.
J. Pers. Med. 2024, 14(6), 646; https://doi.org/10.3390/jpm14060646
Submission received: 12 May 2024 / Revised: 5 June 2024 / Accepted: 14 June 2024 / Published: 17 June 2024
(This article belongs to the Section Disease Biomarker)

Abstract

:
In this study, we evaluated the discharge status of patients with type 2 diabetes mellitus and SARS-CoV-2 infection, focusing on the inflammatory profile through biomarkers such as procalcitonin, CRP, LDH, fibrinogen, ESR, and ferritin, as well as electrolyte levels and the prior diagnosis of diabetes or its identification at the time of hospitalization. We assessed parameters at discharge for 45 patients admitted to the Clinical Hospital “Gavril Curteanu” Oradea between 21 October 2021, and 31 December 2021, randomly selected, having as the main inclusion criteria the positive RT-PCR rapid antigen test for viral infection and the diagnosis of type 2 diabetes. At discharge, patients with type 2 diabetes registered significantly lower mean procalcitonin levels among those who survived compared to those who died from COVID-19. In our study, ferritin and hemoglobin values in individuals with type 2 diabetes were outside the reference range at discharge and correlated with severe or moderate forms of COVID-19 infection. Additionally, elevated ferritin levels at discharge were statistically associated with hypokalemia and elevated levels of ESR at discharge. Another strong statistically significant correlation was identified between high CRP levels at discharge, strongly associated (p < 0.001) with elevated LDH and fibrinogen levels in patients with type 2 diabetes and SARS-CoV-2 viral infection. The increase in CRP was inversely statistically associated with the tendency of serum potassium to decrease at discharge in patients with type 2 diabetes and COVID-19. Identifying type 2 diabetes metabolic pathology at the time of hospitalization for SARS-CoV-2 infection, compared to pre-infection diabetes diagnosis, did not significantly influence the laboratory parameter status at the time of discharge. At the discharge of patients with type 2 diabetes and viral infection with the novel coronavirus, procalcitonin was significantly reduced in those who survived COVID-19 infection, and disease severity was significantly correlated with hyperferritinemia and decreased hemoglobin at discharge. Hyperferritinemia in patients with type 2 diabetes and COVID-19 at discharge was associated with hypokalemia and persistent inflammation (quantified by ESR at discharge). The low number of erythrocytes at discharge is associated with maintaining inflammation at discharge (quantified by the ESR value).

1. Introduction

In December 2019, the entire world witnessed the emergence of respiratory infection outbreaks and pneumonia in Wuhan, China, caused by a new type of coronavirus initially named 2019-nCoV, later identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus spread rapidly among humans, leading to the COVID-19 pandemic at the beginning of 2020, with significant medical and socio-economic implications [1]. Over time, two other types of beta-coronaviruses have been implicated in severe respiratory infections transmitted from different animal species to humans: SARS-CoV in 2002 and MERS-CoV in 2012. However, while these viruses belong to the same large family of Coronaviridae, SARS-CoV-2 has had the largest pandemic impact, with the most rapid spread and numerous severe forms and complications affecting populations globally [2,3]. SARS-CoV-2 is a single-stranded RNA virus in the structure of which non-structural and structural proteins have been identified. Among these, a significant role is played by the spike S structural surface protein, which is crucial in the virus’s pathogenesis and entry into cells. Through its S1 subunit, it attaches to receptors on the cell surface, and through S2, it mediates membrane fusion [4,5]. In addition to the spike protein, other structural proteins of the coronavirus include the M protein, important in viral assembly and the most abundant one; the E envelope protein, the smallest one, with three binding domains, playing a role in assembly and virulence; and the nucleocapsid N protein with five RNA-binding domains [6,7,8]. The functional receptor of SARS-CoV-2 to which the spike protein binds is similar to that of SARS-CoV and is represented by the angiotensin-converting enzyme 2 (ACE2), a component of the renin–angiotensin–aldosterone system [9]. As of 3 March 2024, the World Health Organization has reported an impressive number of SARS-CoV-2 infections, specifically 774,834,251 declared cases, with 7,037,007 deaths [10].
There is a wide list of various biomarkers associated with COVID-19 whose concentration depends on the infection severity, being included in 4 big classes: hematological, biochemical, coagulation, and inflammatory biomarkers (Table 1) [11]. In most cases, SARS-CoV-2 leads to multiple organ/system damage; therefore, the analysis of several biomarkers is crucial for dysfunction monitoring. Laboratory biomarkers play a vital role in the diagnosis and prognosis of patients with multiorgan involvement of COVID-19 (respiratory, cardiovascular, neurologic systems, inflammation, coagulation and hemostasis, metabolic function, kidney and liver function), and the testing time is also important [12,13,14].
Chronic inflammation and insulin resistance associated with type 2 diabetes, including the NF-Kappa-B pathway, which plays an essential role in the body’s response to inflammation, are further exacerbated by the SARS-CoV-2 infection. The increase in proinflammatory cytokines and the onset of cytokine storms can lead to multiple organ failures in the context of COVID-19 [15,16]. Procalcitonin is a precursor protein of calcitonin and serves as a marker associated with inflammation, but particularly with septic conditions more frequently, often but not exclusively, linked to bacterial superinfection, playing a role in the severity of COVID-19 [17,18]. C-reactive protein (CRP) is an acute-phase protein synthesized in the liver, serving as a crucial indicator of systemic inflammation. It is associated with severe forms of viral infection with the novel coronavirus, and it can act as an independent factor for mortality depending on the genetic polymorphism of CRP in COVID-19 [19,20,21]. The increase in CRP and procalcitonin levels in patients with diabetes and COVID-19 has been mentioned in the literature as being associated with acute complications of type 2 diabetes, including difficult-to-control hyperglycemia, diabetic ketoacidosis, and hyperosmolar hyperglycemic syndrome [22]. Lactate dehydrogenase (LDH) is an enzyme from the oxidoreductase class that also acts as an acute-phase reactant in systemic inflammation. In COVID-19 infection, LDH has been associated with a negative prognosis and increased severity since the beginning of the pandemic. Its elevation may be linked to organic damage and hypoxia [23]. The increase in LDH as a nonspecific enzyme, starting from the eighth day of SARS-CoV-2 infection, has been reported in studies in the literature, and it has been the most important risk factor for mortality in COVID-19 patients [24]. Furthermore, in COVID-19 infection, LDH levels as a marker of oxidative stress have been shown to correlate with ambient oxygen saturation, anisocytosis, and disease severity [25]. Another acute-phase protein is fibrinogen, the precursor of fibrin, which consists of two subunits with three polypeptide chains of Aalpha, Bbeta, and γ. Levels of fibrinogen variants have been associated with severe forms of SARS-CoV-2 infection [26,27]. This finding was also presented in our previous studies, which included data from patients at the time of admission [28,29]. D-dimers represent a fibrin degradation product, and high levels of d-dimers are associated with prothrombotic risk, lung injury, and severe forms of COVID-19 [30,31]. Ferritin is the major intracellular iron-storage protein, and hyperferritinemia is associated with severe forms of SARS-CoV-2 viral infection, which is an independent factor in mortality [32]. SARS-CoV-2 viral infection causes alteration of hemoglobin, red blood cells, and ESR levels due to oxidative stress and inflammation; hematological parameters are markers of severe forms of viral infection [33]. Also, an imbalance of electrolytes, such as hyponatremia, hypokalemia, or hypocalcemia, may be an independent prognostic factor or severity in COVID-19 [34,35,36].
In the current study, we analyzed the laboratory parameters at the discharge of patients with SARS-CoV-2 infection who also have type 2 diabetes mellitus. The aim of this study was to evaluate biomedical parameters at discharge in individuals with type 2 diabetes and SARS-CoV-2 infection, considering significant deviations from reference biological intervals and the influence of the clinical form of SARS-CoV-2 infection. Another objective of this study was to compare the mean of various biomedical parameters at discharge in individuals with type 2 diabetes and SARS-CoV-2 infection based on pre-existing diabetes or diabetes diagnosed at the time of hospitalization.

2. Material and Methods

2.1. Study Design

This study was based on 45 patients hospitalized at the Clinical Hospital “Gavril Curteanu” Oradea, the actual Bihor County Emergency Hospital, Coposu location, between 21 October 2021 and 31 December 2021, randomly selected, having as the main inclusion criteria the positive RT-PCR (reverse transcription polymerase chain reaction) rapid antigen test for viral infection and the diagnosis of type 2 diabetes.
This research was conducted in accordance with the Helsinki Declaration, and the protocol was approved by the Ethics Committee of the Clinical Hospital “Gavril Curteanu” Oradea (No. 32652/16 November 2020) and by the Ethics Committee of the University of Oradea (No. 5/A, 21 September 2020). All patients included in this study provided written consent to participate in this research.
The inclusion criteria were SARS-CoV-2 virus infection confirmed by a positive RT-PCR/rapid antigen test and the presence of type 2 diabetes, whether pre-existing or newly diagnosed at the time of hospitalization. The exclusion criteria from the group of patients included the absence of infection with the SARS-CoV-2 virus by negative RT-PCR/rapid antigen test, the absence of type 2 diabetes, or the presence of type 1 diabetes.

2.2. Data Collection

The data were collected in an EXCEL file, including the following biomedical parameters at discharge: procalcitonin, CRP, LDH, fibrinogen, ESR (erythrocyte sedimentation rate), ferritin, hemoglobin, erythrocyte count, serum potassium, serum sodium, D-dimers, and the severity of COVID-19 on CT (mild, moderate, and severe forms).

2.3. Statistical Analysis

To perform the statistical calculations, the EXCEL data file, which contained the study data, was converted into an SPSS file, and the statistical processing was performed with the statistical software SPSS version 20. Adequate statistical tests were used for the analysis: the Student’s t-test for independent samples, the Binomial test and Fisher’s exact test, continuous outcomes performed by the Mann–Whitney U test, as well as the non-parametric Spearman. Also, the significance threshold p = 0.05 (=5%) was used for the case when the result of the analysis was significant, and p = 0.01 was also used for the case when the result of the analysis was strongly significant (p < 0.01).

3. Results

In this study, we analyzed laboratory tests at the discharge of patients with type 2 diabetes mellitus, whether pre-existing or newly identified at the time of hospitalization, and SARS-CoV-2 infection, based on the severity form on CT (mild, moderate, or severe). We also conducted mean comparisons, correlations between evaluated parameters, and adherence to the reference interval (Table 1).
According to Table 1, the application of the Binomial Test distinguished the following situations:
(i)
The proportion of values in the reference range (YES) was strongly statistically significantly higher than those that were not in the reference range (NO) (p < 0.001). This occurred for the following parameters at discharge: RBC, Cl, and Na+. All values were within the reference range for K+ at discharge.
(ii)
The proportion of values in the reference range (YES) was statistically significantly lower than those that were not in the reference range (NO) (p < 0.05). This occurred for the next parameters at discharge, such as ferritin, CRP, LDH, procalcitonin, fibrinogen, D-dimer, and ESR.
(iii)
The proportion of values in the reference range (YES) did not differ statistically significantly from those that were not in the reference range (NO) (p ≥ 0.05). This occurred for the parameter Hb at discharge. In cases i and ii, in most situations, it was found that the applied Binomial Test was highly statistically significant, i.e., p < 0.001.
In Table 2, by applying the Fisher test to the contingency table, a statistically significant association (p = 0.039 < 0.05) was obtained between the fact that ferritin values at discharge were not in the biological reference range and the subject having severe or moderate COVID-19 disease.
In Table 3, by applying the Fisher test to the contingency table, a statistically significant association (p = 0.049 < 0.05) was obtained between the fact that hemoglobin values at discharge were outside the biological reference range and the fact that the subject had severe or moderate COVID-19 disease.
From Table 4, based on the Student’s t-test for independent samples, the means of the following parameters at discharge: ferritin, Hb, LDH, fibrinogen, ESR, Na+, K+, and Cl did not differ significantly statistically between the female and male genders (p > 0.05).
Based on the Mann–Whitney non-parametric test (M–W test) for independent samples, Table 5 indicated that the means of the next parameters at discharge (LDH, CRP, procalcitonin, D-dimers, and RBC) did not differ significantly by gender (p > 0.05).
Biomedical variables in this study did not significantly differ statistically between urban and rural environments, as observed in Table 6.
Most of the biomedical variables in this study did not statistically significantly differ based on the severity of COVID-19 (a mild, moderate, or severe form of COVID-19). However, statistically significant differences were observed for the following parameters at discharge: Ferritin, where the mean for the group of subjects with at most moderate COVID was statistically significantly lower than those with severe COVID (t-test, p < 0.05); LDH, where the mean for the group of subjects with at most moderate COVID was statistically significantly lower than those with severe COVID (t-test, p < 0.01); and CRP, where the mean for the group of subjects with at most moderate COVID was lower than those with severe COVID, although not statistically significant (Table 7).
Statistically significant differences were observed in the next parameters at discharge: ferritin, where the mean for the survivor group was significantly lower than that of the deceased (t-test, p < 0.05); LDH, where the mean for the survivor group was strongly statistically significantly lower than that of the deceased (t-test, p < 0.01); and CRP, where the mean for the survivor group was strongly statistically significantly lower than that of the deceased (Mann–Whitney test, p < 0.01) (Table 8).
In relation to pre-existing type 2 diabetes at the time of hospitalization for COVID-19 or its diagnosis upon hospitalization (0 = debut of diabetes, 1 = pre-existing diabetes), most of the study’s biomedical variables did not differ statistically significantly on average (Table 9).
RBC at discharge statistically significantly correlated non-parametrically (Spearman) (p < 0.05) with both Hb at discharge and ESR at discharge. ESR at discharge showed a statistically significant decreasing trend when RBC at discharge increased (Spearman correlation coefficient Ro < 0) (Table 10).
K+ at discharge showed a statistically significant decreasing trend when CRP at discharge increased (Spearman correlation coefficient Ro < 0), while for the other parameters, a statistically significant increase occurred when CRP at discharge increased (Ro > 0). Additionally, strongly statistically significant correlations (p < 0.01) were observed between CRP, LDH, fibrinogen, and K at discharge (Table 11).
K+ at discharge showed a decreasing trend (statistically significant) when ferritin at discharge increased (Pearson correlation coefficient R < 0), while ESR at discharge showed an increasing trend (statistically significant) when ferritin at discharge increased (R > 0) (Table 12).
The ESR at discharge showed a decreasing trend (statistically significant) when the Hb at discharge increased (Pearson correlation coefficient R < 0), while the LDH at discharge exhibited an increasing trend (statistically significant) when the Hb at discharge increased (R > 0) (Table 13).

4. Discussion

In this study, the mean procalcitonin level at discharge was significantly lower in those who survived the viral infection and who were discharged compared to those who died due to SARS-CoV-2. In the literature, an increase in procalcitonin levels in individuals with SARS-CoV-2 infection in the intensive care unit has been associated with an unfavorable prognosis [37]. In another prospective cohort study, an increase in inflammatory parameters was observed in individuals with severe forms of COVID-19 infection [38]. In a retrospective study, the relationship between increased D-dimer levels, hyperferritinemia, and severe forms of infection was highlighted and correlated with transfer to intensive care and the need for intubation and mechanical ventilation [39].
In our study, we analyzed various parameters at discharge and identified an association between ferritin values outside the reference range at discharge and severe or moderate forms of COVID-19 infection in patients with type 2 diabetes. A similar pattern was observed between hemoglobin values at discharge and moderate and severe forms of COVID-19 infection in patients with type 2 diabetes. Ferritin at discharge in type 2 diabetic patients with at most moderate forms of COVID-19 infection was statistically significantly lower (p < 0.05) compared to those with severe disease. Studies in the literature have shown higher ferritin levels in individuals with diabetes and SARS-CoV-2 compared to patients without diabetes, and much higher ferritin levels in women compared to men who had the viral infection [40,41].
Another aspect of our study is that the mean ferritin level at discharge in diabetic patients who survived the viral infection was statistically significantly lower than in those who died (p < 0.05), and the mean LDH level at discharge was strongly statistically significantly lower in survivors (p < 0.001), along with the mean CRP level at discharge (p < 0.001). Consistent with our study, data from the literature showed elevated levels of LDH, CRP, fibrinogen, and ferritin as biomarkers of high infectious mortality in the context of the novel coronavirus [42].
Regarding the increased ferritin level at discharge, it was statistically associated with decreased potassium levels at discharge and increased ESR levels at discharge, and the mean ferritin levels at discharge were associated with the severity of COVID-19 infection. Hypokalemia has been mentioned in the literature as a marker of severity and has been associated with intensive care unit admission [43].
Changes in hematological parameters in the context of SARS-CoV-2 infection have been mentioned in certain studies regarding the trend of decreased red blood cell count and hemoglobin levels in patients who have contracted the virus [44]. Faghih Dinevari, M., Somi, M.H., and Sadeghi Majd, E. et al. have described a link between the negative prognosis of SARS-CoV-2 infection in the general population and the presence of anemia in infected patients [45].
In our research, we identified that the LDH value at discharge in individuals with metabolic pathology, such as type 2 diabetes, who had mild and moderate forms of viral infection was significantly lower (p < 0.001) than in those patients who had severe forms. CRP at discharge in patients with type 2 diabetes and COVID-19 was lower in those with mild and moderate forms than in those with severe forms on chest CT, however, without statistically significant significance.
Another identified correlation was regarding the high levels of CRP at discharge, strongly statistically associated (p < 0.001) with the increase in LDH and fibrinogen levels in patients with type 2 diabetes and SARS-CoV-2 viral infection. On the other hand, the increase in CRP was inversely correlated with the tendency for serum potassium to decrease at discharge in patients with diabetes. The decreasing trend in potassium was also correlated with hyperferritinemia and increased ESR at discharge.
In another comparative study between symptomatic and asymptomatic forms of COVID-19, the levels of ferritin, glucose, CRP, and D-dimers in the context of SARS-CoV-2 infection were described in relation to severe forms of viral pathology [46].
Similarly, we observed that the decreasing trend in ESR was correlated with high levels of hemoglobin at the end of hospitalization. We identified a statistically significant direct correlation between the increase in hemoglobin and the increase in LDH.
Among the parameters involved in iron metabolism, we identified a statistically significant non-parametric correlation between the number of erythrocytes at discharge (RBC) and the value of ESR at discharge in patients with type 2 diabetes and COVID-19 infection, with ESR showing a decreasing trend as the number of erythrocytes increased.
The decreased number of erythrocytes in diabetic patients with SARS-CoV-2 infection has been mentioned in the specialized literature [47,48]. We identified a statistically significant non-parametric correlation at discharge between the number of erythrocytes and the serum hemoglobin level in the patients included in this study.
Some parameters at discharge, such as hemoglobin, the number of erythrocytes, and fibrinogen, as well as the other parameters analyzed, did not show statistically significant differences based on the gender of the diabetic patients included in our study, nor based on their geographical origin.
In a literature study conducted in Heidelberg, Germany, gender differences were mentioned for ferritin, serum iron, and transferrin, which were more pronounced in male patients. However, only serum iron and ferritin could be associated with more severe forms of COVID-19 infection [49].
The detection of diabetes for the first time at the time of hospitalization for COVID-19 infection or the pre-existence of the diagnosis of type 2 diabetes did not represent a statistically significant differentiating factor regarding the values of biological parameters at discharge in the patients from our study. Among the limitations of our study, we mention the small sample size and the fact that the study was conducted at a single center.

5. Conclusions

Throughout the hospitalization of individuals with type 2 diabetes, whether pre-existing or diagnosed at the time of admission, and SARS-CoV-2 virus infection, it is important to evaluate laboratory parameters at the time of discharge, considering the severity of the viral infection. This comprehensive approach supports clinicians and, most importantly, patients in clinical, paraclinical, and therapeutic management. In this study, we evaluated laboratory analyses at discharge in individuals with metabolic disorders such as type 2 diabetes and viral infection with the novel coronavirus, focusing on significant deviations from the reference range, clinical form of infection on CT scans, comparisons of means of parameters at discharge, various correlations between parameters, and the timing of diabetes diagnosis.
Thus, the diagnosis of type 2 diabetes at the time of admission or pre-existing diabetes prior to hospitalization did not significantly influence the laboratory results at discharge. However, increased procalcitonin, hyperferritinemia, decreased hemoglobin, and decreased red blood cell count at discharge were statistically significant severity markers in patients with type 2 diabetes. On the other hand, hyperferritinemia at discharge was correlated with changes in electrolytes, specifically a decrease in serum potassium, and persistent inflammation indicated by an elevated ESR at discharge. The decrease in potassium was significantly correlated with another inflammatory marker, namely an increase in C-reactive protein. These values were not influenced by the subjects’ gender or whether they originated from urban or rural environments. The mean of procalcitonin, ferritin, LDH, and CRP levels at discharge were significantly lower in those who survived the viral infection and who were discharged compared to those who died due to the SARS-CoV-2 viral infection.

Author Contributions

Conceptualization, P.-A.R. and M.E.M.; methodology, L.G.V. and Ș.Ț.; software, Ș.Ț.; validation, L.G.V., M.E.M.; formal analysis, L.F.; investigation, P.-A.R., F.M.; resources, P.-A.R., D.E.B.; data curation, Ș.Ț.; writing—original draft preparation, P.-A.R.; writing—review and editing, L.F.; visualization, D.E.B.; supervision, F.M.; project administration, L.F.; funding acquisition L.F., All authors have read and agreed to the published version of the manuscript.

Funding

The research has been funded by the University of Oradea within the Grants Competition “Scientific Research of Excellence Related to Priority Areas with Capitalization through Technology Transfer INO-TRANSFER-UO”, Project No. 324/2021.

Institutional Review Board Statement

This study was conducted in accordance with the Helsinki Declaration, and the protocol was approved by the Ethics Committee of the University of Oradea, No. 5/A, 21 September 2020.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data are contained with in the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

In this manuscript, the following abbreviations are used:
SARS-CoV-2Severe acute respiratory syndrome coronavirus 2
COVID-19Coronavirus disease
ACE2Angiotensin-converting enzyme 2
CRPC reactive protein
RT-PCRReverse transcription polymerase chain reaction
RBCRed blood cell
KPotassium (Kalium)
ClChlorine
NaSodium
HbHemoglobin
CTComputed tomography
LDLLow density cholesterol
ESRErythrocyte sedimentation rate

References

  1. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [Google Scholar] [CrossRef] [PubMed]
  2. La Montagne, J.R.; Simonsen, L.; Taylor, R.J.; Turnbull, J. SARS Research Working Group Co-Chairs, Severe Acute Respiratory Syndrome: Developing a Research Response. J. Infect. Dis. 2024, 189, 634–641. [Google Scholar] [CrossRef] [PubMed]
  3. Who Mers-Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr. 2013, 5, ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8. [Google Scholar] [CrossRef] [PubMed]
  4. Cao, C.; Cai, Z.; Xiao, X.; Rao, J.; Chen, J.; Hu, N.; Yang, M.; Xing, X.; Wang, Y.; Li, M.; et al. Arhitectura genomului ARN SARS-CoV-2 în interiorul virionului. Nat. Commun. 2021, 12, 3917. [Google Scholar] [CrossRef] [PubMed]
  5. Tang, X.; Qian, Z.; Lu, X.; Lu, J. Adaptive Evolution of the Spike Protein in Coronaviruses. Mol. Biol. Evol. 2023, 40, msad089. [Google Scholar] [CrossRef] [PubMed]
  6. Zhang, Z.; Nomura, N.; Muramoto, Y.; Ekimoto, T.; Uemura, T.; Liu, K.; Yui, M.; Kono, N.; Aoki, J.; Ikeguchi, M.; et al. Structure of SARS-CoV-2 membrane protein essential for virus assembly. Nat. Commun. 2022, 13, 4399. [Google Scholar] [CrossRef]
  7. Cubuk, J.; Alston, J.J.; Incicco, J.J.; Singh, S.; Stuchell-Brereton, M.D.; Ward, M.D.; Zimmerman, M.I.; Vithani, N.; Griffith, D.; Wagoner, J.A.; et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun. 2021, 12, 1936. [Google Scholar] [CrossRef] [PubMed]
  8. Javorsky, A.; Humbert, P.O.; Kvansakul, M. Structural basis of coronavirus E protein interactions with human PALS1 PDZ domain. Commun. Biol. 2021, 4, 724. [Google Scholar] [CrossRef]
  9. Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020, 581, 215–220. [Google Scholar] [CrossRef]
  10. WHO. Available online: https://data.who.int/dashboards/covid19/cases?n=c (accessed on 3 March 2024).
  11. Ponti, G.; Maccaferri, M.; Ruini, C.; Tomasi, A.; Ozben, T. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 2020, 57, 389–399. [Google Scholar] [CrossRef]
  12. Pal, M.; Muinao, T.; Parihar, A.; Roy, D.K.; Boruah, H.P.D.; Mahindroo, N.; Khan, R. Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise. Biosens. Bioelectron. X 2022, 12, 100281. [Google Scholar] [CrossRef] [PubMed]
  13. Battaglini, D.; Lopes-Pacheco, M.; Castro-Faria-Neto, H.C.; Pelosi, P.; Rocco, P.R.M. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Front. Immunol. 2022, 13, 857573. [Google Scholar] [CrossRef] [PubMed]
  14. Samprathi, M.; Jayashree, M. Biomarkers in COVID-19: An Up-To-Date Review. Front. Pediatr. 2021, 8, 607647. [Google Scholar] [CrossRef] [PubMed]
  15. Mozafari, N.; Azadi, S.; Mehdi-Alamdarlou, S.; Ashrafi, H.; Azadi, A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Med. Hypotheses 2020, 143, 110111. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  16. Ho, G.; Ali, A.; Takamatsu, Y.; Wada, R.; Masliah, E.; Hashimoto, M. Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2. Drug Discov. Today 2021, 26, 2036–2044. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  17. Bajić, D.; Matijašević, J.; Andrijević, L.; Zarić, B.; Lalić-Popović, M.; Andrijević, I.; Todorović, N.; Mihajlović, A.; Tapavički, B.; Ostojić, J. Prognostic Role of Monocyte Distribution Width, CRP, Procalcitonin and Lactate as Sepsis Biomarkers in Critically Ill COVID-19 Patients. J. Clin. Med. 2023, 12, 1197. [Google Scholar] [CrossRef] [PubMed]
  18. Hu, R.; Han, C.; Pei, S.; Yin, M.; Chen, X. Procalcitonin levels in COVID-19 patients. Int. J. Antimicrob. Agents 2020, 56, 106051. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  19. Gebrecherkos, T.; Challa, F.; Tasew, G.; Gessesse, Z.; Kiros, Y.; Gebreegziabxier, A.; Abdulkader, M.; Desta, A.A.; Atsbaha, A.H.; Tollera, G.; et al. Prognostic Value of C-Reactive Protein in SARS-CoV-2 Infection: A Simplified Biomarker of COVID-19 Severity in Northern Ethiopia. Infect. Drug Resist. 2023, 16, 3019–3028. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  20. Fritea, L.; Fritea, L.; Sipponen, M.; Sipponen, M.; Antonescu, A.; Antonescu, A.; Miere, F.G.; Miere, F.G.; Chirla, R.; Chirla, R.; et al. Relationship between Pre-Existing Conditions in Covid-19 Patients and Inflammation. Pharmacophore 2022, 13, 41–48. [Google Scholar] [CrossRef]
  21. Mofrad, S.S.; Amnieh, S.B.; Pakzad, M.R.; Zardadi, M.; Jajin, M.G.; Anvari, E.; Moghaddam, S.; Fateh, A. The death rate of COVID-19 infection in different SARS-CoV-2 variants was related to C-reactive protein gene polymorphisms. Sci. Rep. 2024, 14, 703. [Google Scholar] [CrossRef]
  22. Tao, L.-C.; Shu, H.; Wang, Y.; Hou, Q.; Li, J.-J.; Huang, X.-L.; Hua, F. Inflammatory biomarkers predict higher risk of hyperglycemic crises but not outcomes in diabetic patients with COVID-19. Front. Endocrinol. 2024, 15, 1287795. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  23. Shokr, H.; Marwah, M.K.; Siddiqi, H.; Wandroo, F.; Sanchez-Aranguren, L.; Ahmad, S.; Wang, K.; Marwah, S. Lactate Dehydrogenase/Albumin To-Urea Ratio: A Novel Prognostic Maker for Fatal Clinical Complications in Patients with COVID-19 Infection. J. Clin. Med. 2023, 12, 19. [Google Scholar] [CrossRef]
  24. Nakakubo, S.; Unoki, Y.; Kitajima, K.; Terada, M.; Gatanaga, H.; Ohmagari, N.; Yokota, I.; Konno, S. Serum Lactate Dehydrogenase Level One Week after Admission Is the Strongest Predictor of Prognosis of COVID-19: A Large Observational Study Using the COVID-19 Registry Japan. Viruses 2023, 15, 671. [Google Scholar] [CrossRef] [PubMed]
  25. Alonso-Bernáldez, M.; Cuevas-Sierra, A.; Micó, V.; Higuera-Gómez, A.; Ramos-Lopez, O.; Daimiel, L.; Dávalos, A.; Martínez-Urbistondo, M.; Moreno-Torres, V.; Ramirez de Molina, A.; et al. An Interplay between Oxidative Stress (Lactate Dehydrogenase) and Inflammation (Anisocytosis) Mediates COVID-19 Severity Defined by Routine Clinical Markers. Antioxidants 2023, 12, 234. [Google Scholar] [CrossRef] [PubMed]
  26. de Vries, J.J.; Visser, C.; van Ommen, M.; Rokx, C.; van Nood, E.; van Gorp, E.C.M.; Goeijenbier, M.; Akker, J.P.C.v.D.; Endeman, H.; Rijken, D.C.; et al. Levels of Fibrinogen Variants Are Altered in Severe COVID-19. TH Open 2023, 7, e217–e225. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  27. Risman, R.A.; Belcher, H.A.; Ramanujam, R.K.; Weisel, J.W.; Hudson, N.E.; Tutwiler, V. Comprehensive Analysis of the Role of Fibrinogen and Thrombin in Clot Formation and Structure for Plasma and Purified Fibrinogen. Biomolecules 2024, 14, 230. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  28. Restea, P.-A.; Muresan, M.; Voicu, A.; Jurca, T.; Pallag, A.; Marian, E.; Vicaș, L.G.; Jeican, I.I.; Crivii, C.-B. Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection. J. Pers. Med. 2023, 13, 392. [Google Scholar] [CrossRef] [PubMed]
  29. Reștea, P.-A.; Țigan, Ș.; Vicaș, L.G.; Fritea, L.; Marian, E.; Jurca, T.; Pallag, A.; Mureșan, I.L.; Moisa, C.; Micle, O.; et al. Serum Level of Ceruloplasmin, Angiotensin-Converting Enzyme and Transferrin as Markers of Severity in SARS-CoV-2 Infection in Patients with Type 2 Diabetes. Microbiol. Res. 2023, 14, 1670–1686. [Google Scholar] [CrossRef]
  30. Trimaille, A.; Thachil, J.; Marchandot, B.; Curtiaud, A.; Leonard-Lorant, I.; Carmona, A.; Matsushita, K.; Sato, C.; Sattler, L.; Grunebaum, L.; et al. D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. J. Clin. Med. 2021, 10, 39. [Google Scholar] [CrossRef]
  31. Qeadan, F.; Tingey, B.; Gu, L.Y.; Packard, A.H.; Erdei, E.; Saeed, A.I. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. Viruses 2021, 13, 419. [Google Scholar] [CrossRef]
  32. Kurian, S.J.; Mathews, S.P.; Paul, A.; Viswam, S.K.; Nagri, S.K.; Miraj, S.S.; Karanth, S. Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facility. Clin. Epidemiol. Glob. Health 2023, 21, 101295. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  33. Russo, A.; Tellone, E.; Barreca, D.; Ficarra, S.; Laganà, G. Implication of COVID-19 on Erythrocytes Functionality: Red Blood Cell Biochemical Implications and Morpho-Functional Aspects. Int. J. Mol. Sci. 2022, 23, 2171. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  34. Berni, A.; Malandrino, D.; Corona, G.; Maggi, M.; Parenti, G.; Fibbi, B.; Poggesi, L.; Bartoloni, A.; Lavorini, F.; Fanelli, A.; et al. Serum sodium alterations in SARS CoV-2 (COVID-19) infection: Impact on patient outcome. Eur. J. Endocrinol. 2021, 185, 137–144. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  35. Alfano, G.; Ferrari, A.; Fontana, F.; Perrone, R.; Mori, G.; Ascione, E.; Magistroni, R.; Venturi, G.; Pederzoli, S.; Margiotta, G.; et al. Hypokalemia in Patients with COVID-19. Clin. Exp. Nephrol. 2021, 25, 401–409. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  36. Reștea, P.-A.; Tigan, Ș.; Fritea, L.; Vicaș, L.G.; Marian, E.; Mureșan, M.E.; Stefan, L. Serum Calcium and Magnesium Levels in Patients with Type 2 Diabetes and COVID-19 Infection Requiring Hospitalization—Correlations with Various Parameters. Microbiol. Res. 2024, 15, 431–446. [Google Scholar] [CrossRef]
  37. Ince, F.M.; Alkan Bilik, O.; Ince, H. Evaluating Mortality Predictors in COVID-19 Intensive Care Unit Patients: Insights into Age, Procalcitonin, Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Ferritin Lactate Index. Diagnostics 2024, 14, 684. [Google Scholar] [CrossRef] [PubMed]
  38. Trofin, F.; Nastase, E.V.; Roșu, M.F.; Bădescu, A.C.; Buzilă, E.R.; Miftode, E.G.; Manciuc, D.C.; Dorneanu, O.S. Inflammatory Response in COVID-19 Depending on the Severity of the Disease and the Vaccination Status. Int. J. Mol. Sci. 2023, 24, 8550. [Google Scholar] [CrossRef] [PubMed]
  39. Hakami, A.; Altubayqi, T.; Qadah, E.A.; Zogel, B.; Alfaifi, S.M.; Refaei, E.; Sayed, A.; Alhazmi, L.; Sayegh, M.; Alamer, A.; et al. Biochemical Analysis of Ferritin and D-dimer in COVID-19 Survivors and Non-survivors. Cureus 2023, 15, e45389. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  40. Madfoon, Z.; Mezher, M.; Madfoon, S. Comparison of Serum Ferritin Levels between Diabetic Patients with COVID-19 and Non-Diabetic Patients with COVID-19 Based on Age Groups and Gender. Iran. J. War Public Health 2022, 14, 165–170. Available online: http://ijwph.ir/article-1-1114-en.html (accessed on 24 April 2024).
  41. Liani, F.N.; Mudjanarko, S.W.; Novida, H. The role of serum ferritin level and disease severity in COVID-19 with type 2 diabetes mellitus patients. Bali Med. J. 2022, 11, 1805–1810. [Google Scholar] [CrossRef]
  42. Casillas, N.; Ramón, A.; Torres, A.M.; Blasco, P.; Mateo, J. Predictive Model for Mortality in Severe COVID-19 Patients across the Six Pandemic Waves. Viruses 2023, 15, 2184. [Google Scholar] [CrossRef] [PubMed]
  43. Moreno-Pérez, O.; Leon-Ramirez, J.-M.; Fuertes-Kenneally, L.; Perdiguero, M.; Andres, M.; Garcia-Navarro, M.; Ruiz-Torregrosa, P.; Boix, V.; Gil, J.; Merino, E.; et al. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. Int. J. Infect. Dis. 2020, 100, 449–454. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  44. Urbano, M.; Costa, E.; Geraldes, C. Hematological changes in SARS-COV-2 positive patients. Hematol. Transfus. Cell Ther. 2022, 44, 218–224. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  45. Dinevari, M.F.; Somi, M.H.; Majd, E.S.; Farhangi, M.A.; Nikniaz, Z. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: A prospective study in Iran. BMC Infect Dis. 2021, 21, 170. [Google Scholar] [CrossRef] [PubMed]
  46. Pérez-García, N.; García-González, J.; Requena-Mullor, M.; Rodríguez-Maresca, M.Á.; Alarcón-Rodríguez, R. Comparison of Analytical Values D-Dimer, Glucose, Ferritin and C-Reactive Protein of Symptomatic and Asymptomatic COVID-19 Patients. Int. J. Environ. Res. Public Health 2022, 19, 5354. [Google Scholar] [CrossRef] [PubMed]
  47. Akbariqomi, M.; Hosseini, M.S.; Rashidiani, J.; Sedighian, H.; Biganeh, H.; Heidari, R.; Moghaddam, M.M.; Farnoosh, G.; Kooshki, H. Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: A single-center, retrospective study in Iran. Diabetes Res. Clin. Pract. 2020, 169, 108467. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  48. Gavkare, A.M.; Nanaware, N.; Rayate, A.S.; Mumbre, S.; Nagoba, B.S. COVID-19 associated diabetes mellitus: A review. World J. Diabetes 2022, 13, 729–737. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  49. Hippchen, T.; Altamura, S.; Muckenthaler, M.U.; Merle, U. Hypoferremia is Associated with Increased Hospitalization and Oxygen Demand in COVID-19 Patients. Hemasphere 2020, 4, e492. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Table 1. The adherence to the reference biological intervals of the parameters at discharge.
Table 1. The adherence to the reference biological intervals of the parameters at discharge.
Evaluated ParametersRef. IntervalNObs. ProportionTested ProportionBinomial Test, p
Serum ferritinGroup 1NO300.730.270.0001
Group 2YES110.27--
Total-411.00--
HemoglobinGroup 1YES220.520.480.339
Group 2NO200.48--
Total-421.00--
RBCGroup 1YES320.780.220.0001
Group 2NO90.22--
Total-411.00--
CRPGroup 1NO370.880.120.0001
Group 2YES50.12--
Total 421.00--
LDHGroup 1NO340.810.190.0001
Group 2YES80.19--
Total 421.00--
ProcalcitoninGroup 1NO380.900.100.0001
Group 2YES40.10--
Total 421.00--
FibrinogenGroup 1NU290.780.220.0001
Group 2DA80.22--
Total 371.00--
D-dimersGroup 1NO290.760.240.0001
Group 2YES90.24--
Total 381.00--
ESRGroup 1NO260.670.330.0001
Group 2YES130.33--
Total 391.00--
Na+Group 1YES260.630.500.0001
Group 2NO150.37--
Total 411.00--
K+Group 1NO411.000.500.0001
Total 411.00--
ClGroup 1YES320.780.220.0001
Group 2NO90.22--
Total 411.00--
Table 2. The association between ferritin at discharge and COVID-19 severity.
Table 2. The association between ferritin at discharge and COVID-19 severity.
Ref.
Int.
COVID-19 Severity FormsTotalFisher TestOR
Moderate and SevereMildp L.ILS.
Serum ferritinYES291300.01416.5711.594172.307
NO7411----
Total36541----
OR = 16.571 > 1 (1.594 ≤ OR ≤ 172.307) shows the ratio of those with severe or moderate forms of COVID-19 to those with mild forms among subjects with ferritin levels outside the reference range to the same ratio among subjects with ferritin levels within the reference range.
Table 3. The association between Hb levels at discharge and the severity of COVID-19.
Table 3. The association between Hb levels at discharge and the severity of COVID-19.
Ref.
Int.
COVID-19 Severity FormsTotalF TestRR
Moderate and SevereMildp-L.ILS.
HbYES200200.0491.2941.0321.623
NO17522----
Total37542----
Relative Risk RR = 1.294 > 1 was statistically significant, as indicated by its confidence interval presented in Table 3.
Table 4. The comparison of quantitative biomedical parameters at discharge, such as ferritin, Hb, LDH, and fibrinogen by gender.
Table 4. The comparison of quantitative biomedical parameters at discharge, such as ferritin, Hb, LDH, and fibrinogen by gender.
GenderNMeanStd. Deviationt-Test, p
FerritinF26605.085615.4830.080
M151022.693867.771-
HbF2612.6771.6630.157
M1613.5562.280-
LDHF26391.413192.0130.280
M16489.563387.699-
ESRF2547.48029.1580.902
M1446.28628.009-
Na+F25138.1013.9950.657
M16137.5004.514-
K+F254.2040.7300.334
M163.9870.631-
ClF25101.5363.6430.231
M16100.0254.224-
Table 5. Mann–Whitney non-parametric test (M–W test) for independent samples.
Table 5. Mann–Whitney non-parametric test (M–W test) for independent samples.
GenderNMeanStd. Deviation.M–W Test, p
LDHF26391.413192.0130.856
M16489.563387.699-
CRPF2642.87553.5390.897
M1681.398122.251-
ProcalcitoninF261.1000.9020.623
M162.1633.465-
D-dimersF242324.8752731.1180.116
M141038.929855.329-
RBCF254.4400.5830.673
M164.5630.629-
Table 6. Comparison of the means of biomedical parameters at discharge by environment (0 = urban, 1 = rural).
Table 6. Comparison of the means of biomedical parameters at discharge by environment (0 = urban, 1 = rural).
EnvironmentNMeanStd. Deviation.pM–W Test, p
Ferritin018643.606416.7660.386T
123847.291912.041--
Hb01913.1212.1190.745T
12312.9221.828--
RBC0184.4440.6160.470M–W
1234.5220.593--
CRP01963.14878.7370.423M–W
12352.92694.835--
LDH019417.842339.8540.822T
123437.858232.439--
Procalcitonin0191.0010.6930.750M–W
1231.9212.971--
Fibrinogen014477.671133.0240.552T
123447.639155.700--
D-dimers0152120.5332021.3920.194M–W
1231675.3912492.591--
ESR01753.82433.6510.194T
12241.81823.006--
Na+018138.2003.2850.656T
123137.6064.792--
K+0184.0860.7710.789T
1234.1460.643--
Cl018101.2444.4190.671T
123100.7133.527--
Table 7. Comparison of the mean values of biomedical parameters at discharge by severity of COVID (1 = mild form, 2 = moderate form, 3 = severe form of COVID).
Table 7. Comparison of the mean values of biomedical parameters at discharge by severity of COVID (1 = mild form, 2 = moderate form, 3 = severe form of COVID).
COVID-19 SeverityNMeanStd. Deviation.pM–W Test, T
FerritinMild and moderate forms18518.644353.389-T
Severe forms23945.087897.2800.046-
HbMild and moderate forms1813.3611.384-T
Severe forms2412.7502.2680.287-
RBCMild and moderate forms174.5880.5070.317M–W
Severe forms244.4170.654--
CRPMild and moderate forms1817.74721.2420.213M–W
Severe forms2487.403104.873--
LDHMild and moderate forms18282.667131.5030.003T
Severe forms24538.406316.578--
ProcalcitoninMild and moderate forms181.4132.1270.258M–W
Severe forms241.5742.418--
FibrinogenMild and moderate forms16485.150121.6270.350T
Severe forms21439.081162.797--
D-dimersMild and moderate forms161027.8751020.4990.310M–W
Severe forms222449.8182771.788--
ESRMild and moderate forms1646.06326.2720.859T
Severe forms2347.73930.329--
Na+Mild and moderate forms17137.5414.6900.679T
Severe forms24138.0973.829--
K+Mild and moderate forms174.3440.5380.081T
Severe forms243.9600.756--
ClMild and moderate forms17101.1944.3880.737T
Severe forms24100.7713.603--
Table 8. Comparison of the mean of biomedical parameters at discharge by the DEATH parameter (0 = NO, 1 = YES).
Table 8. Comparison of the mean of biomedical parameters at discharge by the DEATH parameter (0 = NO, 1 = YES).
DeathNMeanStd. Deviation.pM–W Test, T
FerritinNO33533.900363.198-T
YES81681.7381131.8070.024-
HbNO3412.7941.7910.136T
YES813.9382.404--
RBCNO334.4550.5640.656M–W
YES84.6250.744--
CRPNO3424.60730.2760.000M–W
YES8197.561111.205--
LDHNO34354.375147.4630.000T
YES8745.125472.891--
ProcalcitoninNO341.1561.6180.006M–W
YES82.9883.845--
FibrinogenNO30439.013144.7910.085T
YES7544.671129.031--
D-dimersNO301573.7331710.0710.244M–W
YES82891.2503778.140--
ESRNO3145.09727.2850.404T
YES854.62533.175--
Na+NO33137.5804.1690.376T
YES8139.0504.175--
K+NO334.1990.6480.138T
YES83.7910.820--
ClNO33100.7583.5220.536T
YES8101.7255.419--
Table 9. Comparison of the means of biomedical parameters at discharge by the parameter of pre-existing type 2 diabetes (0 = debut of diabetes, 1 = pre-existing diabetes).
Table 9. Comparison of the means of biomedical parameters at discharge by the parameter of pre-existing type 2 diabetes (0 = debut of diabetes, 1 = pre-existing diabetes).
DMNMeanStd. Dev.pM–W Test, T
Ferritin05720.340449.6860.905T
136763.081771.915--
Hb0613.7331.7590.332T
13612.8921.969--
RBC064.7150.6000.206M–W
1354.3600.565--
CRP0629.67740.5800.661M–W
13662.19692.097--
LDH06361.000115.8640.532T
136440.104301.069--
Procalcitonin060.9580.8290.746M–W
1361.5962.427--
Fibrinogen05359.160185.2730.102T
132474.603136.345--
D-dimers051094.800944.7560.479M–W
1331965.6972429.159--
ESR0534.80015.7230.308T
13448.85329.525--
Na+06135.2003.8630.089T
135138.3244.086--
K+064.2350.4800.665T
1354.1000.728--
Cl0698.7173.5310.131T
135101.3293.877--
Table 10. Non-parametric correlations between the level of RBC at discharge and the quantitative parameters of the study at discharge.
Table 10. Non-parametric correlations between the level of RBC at discharge and the quantitative parameters of the study at discharge.
RBC
Spearman RopN
Hb0.8970.00041
ESR−0.5060.00138
Table 11. Non-parametric correlations between the level of CRP at discharge and the quantitative parameters of the study at discharge.
Table 11. Non-parametric correlations between the level of CRP at discharge and the quantitative parameters of the study at discharge.
CRP
Spearman RopN
Ferritin0.385 0.01341
LDH0.549 0.00042
Procalcitonin0.311 0.04542
Fibrinogen0.448 0.00537
D-dimers0.433 0.00738
K+−0.479 0.00241
Table 12. Pearson parametric correlations between ferritin at discharge and other parameters at discharge.
Table 12. Pearson parametric correlations between ferritin at discharge and other parameters at discharge.
Ferritin
Pearson RpN
ESR0.326 0.04339
K+−0.364 0.02140
Table 13. Parametric correlations (Pearson) between the parameter Hb at discharge and other parameters at discharge.
Table 13. Parametric correlations (Pearson) between the parameter Hb at discharge and other parameters at discharge.
Hb
Pearson RpN
LDH0.423 0.00542
ESR−0.454 0.00439
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Reștea, P.-A.; Țigan, Ș.; Vicaș, L.G.; Fritea, L.; Mureșan, M.E.; Manole, F.; Berdea, D.E. The Relationship between the Laboratory Biomarkers of SARS-CoV-2 Patients with Type 2 Diabetes at Discharge and the Severity of the Viral Pathology. J. Pers. Med. 2024, 14, 646. https://doi.org/10.3390/jpm14060646

AMA Style

Reștea P-A, Țigan Ș, Vicaș LG, Fritea L, Mureșan ME, Manole F, Berdea DE. The Relationship between the Laboratory Biomarkers of SARS-CoV-2 Patients with Type 2 Diabetes at Discharge and the Severity of the Viral Pathology. Journal of Personalized Medicine. 2024; 14(6):646. https://doi.org/10.3390/jpm14060646

Chicago/Turabian Style

Reștea, Patricia-Andrada, Ștefan Țigan, Laura Grațiela Vicaș, Luminita Fritea, Mariana Eugenia Mureșan, Felicia Manole, and Daniela Elisabeta Berdea. 2024. "The Relationship between the Laboratory Biomarkers of SARS-CoV-2 Patients with Type 2 Diabetes at Discharge and the Severity of the Viral Pathology" Journal of Personalized Medicine 14, no. 6: 646. https://doi.org/10.3390/jpm14060646

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop